Target Price | $57.14 |
Price | $28.52 |
Potential |
100.34%
register free of charge
|
Number of Estimates | 22 |
22 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $57.14.
This is
100.34%
register free of charge
$78.00
173.49%
register free of charge
$37.00
29.73%
register free of charge
|
|
A rating was issued by 26 analysts: 17 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
100.34%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 705.14 | 657.33 |
10.48% | 6.78% | |
EBITDA Margin | -64.26% | -86.86% |
52.80% | 35.18% | |
Net Margin | -68.08% | -92.26% |
32.65% | 35.52% |
20 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.04 | -3.84 |
18.75% | 26.32% | |
P/E | negative | |
EV/Sales | 6.37 |
17 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
Redburn Atlantic |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Needham |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Analyst Rating | Date |
---|---|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 03 2025 |
Locked
Redburn Atlantic:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 24 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
Needham:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.